25.16
Ipoglicemia e glucagone
Senza digiuno prolungato, gli individui sani mantengono i livelli di glucosio nel sangue superiori a 80 mg/dL grazie a un sistema controregolatore neu…
Senza digiuno prolungato, gli individui sani mantengono i livelli di glucosio nel sangue >80 mg/dL grazie a un sistema neuroendocrino ben adattato.
Tuttavia, l'ipoglicemia può verificarsi a causa del trattamento del diabete, del tumore pancreatico che produce insulina in eccesso e dell'uso di agenti ipoglicemizzanti in individui non diabetici.
Nei soggetti ipoglicemici, la glicemia scende al di sotto di 70 mg/dL, con conseguente sudorazione, fame, confusione e perdita di coscienza.
L'ipoglicemia può essere rilevata dal monitoraggio domiciliare del glucosio e trattata con glucosio per via orale.
Il glucosio può anche essere somministrato per via endovenosa sotto supervisione.
Per le reazioni ipoglicemiche gravi, viene utilizzato il glucagone ricombinante, che interagisce con il GPCR del glucagone sulle cellule bersaglio, attivando la via di segnalazione.
Il glucagone viene solitamente somministrato per via sottocutanea o endovenosa, con la via intramuscolare preferita durante le emergenze.
Dopo la risposta iniziale, i pazienti devono consumare glucosio o cibo per via orale per prevenire l'ipoglicemia ricorrente.
View the full transcript and gain access to JoVE Core videos
Q1: What blood glucose level defines hypoglycemia?
Hypoglycemia occurs when plasma glucose drops below 70 mg/dL (3.9 mM). Healthy individuals normally maintain blood glucose levels above 80 mg/dL through a well-adapted neuroendocrine counterregulatory system. This threshold is clinically significant because symptoms typically manifest when glucose reaches 60-70 mg/dL, requiring prompt intervention to prevent severe complications.
Q2: What are the main causes of hypoglycemia in clinical practice?
Hypoglycemia primarily results from diabetes treatment, pancreatic tumors producing excess insulin, and glucose-lowering agents used in non-diabetic individuals. Insulin therapy poses the greatest risk, with contributing factors including insulin dose mismatches, increased insulin sensitivity, and concurrent conditions such as adrenal or pituitary insufficiency. In diabetic patients, the glucagon secretory response may become deficient over time, further increasing severe hypoglycemia risk.
Q3: What symptoms indicate hypoglycemia?
Hypoglycemia manifests as sweating, hunger, confusion, paresthesias, palpitations, tremors, and anxiety when plasma glucose reaches 60-70 mg/dL. Severe hypoglycemia can progress to neurological symptoms, seizures, loss of consciousness, and coma. These autonomic and neuroglycopenic symptoms require immediate recognition and treatment to prevent life-threatening complications.
Q4: How does glucagon treat severe hypoglycemia?
Recombinant glucagon interacts with the glucagon GPCR on target cells, activating the Gs-cAMP-PKA signaling pathway to rapidly increase blood glucose. It is administered intravenously, intramuscularly, or subcutaneously, with the intramuscular route preferred during emergencies. Following the initial glucagon response, patients must consume oral glucose or food to prevent recurrent hypoglycemia and maintain stable glucose levels.
Q5: What treatment options are available for hypoglycemia?
Hypoglycemia treatment depends on severity and patient ability to consume food. Oral glucose is the first-line approach for conscious patients. Intravenous glucose can be administered under medical supervision when oral intake is not feasible. For severe hypoglycemic reactions when patients cannot take oral glucose, recombinant glucagon is the emergency treatment of choice.
Q6: Why is home glucose monitoring important in hypoglycemia management?
Home glucose monitoring is crucial for documenting hypoglycemia episodes, enabling timely intervention and appropriate management decisions. Regular monitoring helps identify patterns and risk factors, particularly in diabetic patients at high risk of severe hypoglycemia. This proactive approach allows patients and healthcare providers to adjust treatment regimens and prevent life-threatening hypoglycemic events.
Q7: How do counterregulatory hormones respond to hypoglycemia?
The initial response to hypoglycemia involves reducing endogenous insulin secretion, followed by releasing counterregulatory hormones including epinephrine, norepinephrine, glucagon, growth hormone, and cortisol. These hormones work together to raise blood glucose and restore glucose homeostasis. In diabetic patients with prolonged disease, the glucagon response may become deficient, compromising this critical defense mechanism.